The great disappearing act: Gender parity up the corporate ladder
WEF whitepaper 1/30/2010
by Julie Coffman, Orit Gadiesh and Wendy Miller
In recent years, while women gained ground on gender equality issues like discrimination and harassment, they continued to struggle on gender parity issues like career development and access to leadership positions. To understand the hurdles in the path to parity up the ladder, Bain & Company recently conducted a worldwide survey-in association with the Harvard Business Review-on "Gender Parity in the Workplace." The survey results show that while both men and women aspire to be senior leaders in their organization, fewer women realize their dreams than men. Our survey findings indicate that three major issues block the way to gender parity in many organizations.
Changing the game: The next-generation care management model for payers
Bain Brief 1/27/2010
by Phyllis Yale and Joshua Weisbrod
With the employer-sponsored insurance market in decline, and building pressure from the call for a public option, payers are struggling to keep costs down. In order to do so, they will need to focus on the toughest changes of all: reducing the need for medical care and lowering the cost of care delivery.
The green edge: Why carbon competitiveness matters
Bain Brief 1/15/2010
by Jorge Leis and Kurt Zenz House
Most CEOs get the big picture on carbon competitiveness. Many attend industry forums and contribute their perspectives to the development of government policies. But few CEOs ask how they can use carbon-competitiveness to gain an edge over their competitors. The right answer can ensure the longevity of a company in an increasingly regulated world.
Biosimilars: A marathon, not a sprint
Industry Brief 12/16/2009
by Nils Behnke, Norbert Hueltenschmidt, Andy Pasternak and Karan Singh
While it is hard to predict exactly how--or when--the market for biosimilars will evolve, their potential impact on the global pharmaceuticals industry cannot be ignored. Just as generics emerged as a powerful force in the last two decades, for many in the pharma industry, biosimilars will be a strong agent for change in the future--either through disruption or innovation.
The social and economic impact of private equity in China
12/15/2009
by European Union Chamber of Commerce in China in partnership with Bain & Company
In just 10 years, the private equity industry in China has become a driving force for economic growth, job creation, innovation and entrepreneurial success. Though slowed by the business-cycle downturn, this trend is continuing through the current turbulence. This survey is the contribution of the European Union Chamber of Commerce in China, in partnership with Bain & Company, to evaluate PE's role in China at this important juncture in its development.
|
|
|
Follow us on Twitter